October 30, 2019
Authored and Edited by Kathryn R. Judson; Shana K. Cyr, Ph.D.
On October 18, 2019, FDA issued draft guidance on Drug Master Files, which are optional submissions to FDA that provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products. DMFs can be used to support NDAs, ANDAs, INDs, and BLAs, and information contained in DMFs can also generally be referenced in premarket submissions for devices and animal drugs. The draft guidance revises a previously published draft guidance from September 1989, with most changes involving reorganization of the information.
The FDA intends this guidance to provide information about preparing and submitting DMFs, including by describing the types of DMFs, the information needed in DMF submissions, and FDA’s DMF review processes. The guidance begins by identifying the four DMF types, numbered II through V, noting that Type I was discontinued in 2000. The guidance also discusses the format and delivery of DMF submissions and provides submission recommendations, including some that are specific to DMF type. FDA’s DMF review includes an administrative review followed by a technical review. FDA will contact the DMF holder if there is incomplete administrative information, if additional information is needed to continue a review, if the DMF cannot be used to support approval of the application or allow clinical trials to proceed, or if FDA cannot be assured that a DMF is current.
Readers are encouraged to read the draft guidance, also available on FDA's website.
Food and Drug Administration (FDA), FDA Guidance, new drug application (NDA), Investigational New Drug Application (INDA)
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.